Chong Kun Dang Pharmaceutical Corp. (185750.KS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	1782.8B	1692.4B	1586.4B	1669.4B	1488.3B
Cost of Revenue	1265.2B	1175.2B	1053.8B	1007.2B	945.7B
Gross Profit	517.6B	517.2B	532.6B	662.2B	542.6B
Operating Expenses
R&D Expense	111.4B	154.1B	143.9B	140.2B	176.3B
SG&A Expense	42.6B	142.5B	140.0B	131.4B	116.5B
General & Admin Expense	(43.3B)	25.0B	26.1B	25.0B	22.6B
Selling & Marketing Expense	85.9B	117.5B	113.9B	106.4B	93.9B
Other Expenses	330.9B	140.0B	149.3B	144.0B	140.0B
Total Operating Expenses	449.6B	436.6B	433.1B	415.6B	432.7B
Cost and Expenses	1705.7B	1611.8B	1487.0B	1422.7B	1378.4B
Operating Income (EBIT)	77.2B	80.6B	99.5B	246.6B	109.9B
Non-Operating
Interest Income	6.7B	6.9B	12.4B	5.8B	2.1B
Interest Expense	7.9B	6.7B	8.3B	9.3B	6.8B
Net Interest Income	(1.3B)	220.3M	4.1B	(3.5B)	(4.7B)
Other Non-Op Income/Expense	(318.8M)	1.1B	2.5B	(5.0B)	(12.7B)
Non-Operating Income (excl Interest)	(4.2B)	—	(10.9B)	(4.1B)	5.9B
EBT (Pre-Tax Income)	76.9B	81.7B	102.0B	241.6B	97.2B
Income Tax Expense	(2.7B)	3.8B	(9.4B)	28.0B	17.2B
Bottom Line
Net Income	79.5B	77.8B	109.1B	212.5B	81.0B
Earnings from Cont. Ops	79.6B	77.8B	111.4B	213.6B	80.0B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	77.5B	77.8B	109.1B	212.5B	81.0B
Per Share
Basic EPS	₩5,817	₩5,882	₩8,207	₩16,704	₩6,609
Diluted EPS	₩5,817	₩5,846	₩8,207	₩16,704	₩6,609
Revenue Per Share	₩129,157	₩128,456	₩119,767	₩131,212	₩121,507
Shares
Basic Shares Outstanding	13.8M	13.2M	13.2M	12.7M	12.2M
Diluted Shares Outstanding	13.8M	13.2M	13.2M	12.7M	12.2M
Profitability Metrics
EBITDA	124.0B	125.4B	150.0B	287.6B	137.5B
D&A	45.7B	44.7B	39.7B	37.0B	33.5B
EBIT	78.2B	80.6B	110.3B	250.7B	104.0B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026